8.27

4.55% 0.36

After Hours: 8.40 0.13 +1.57%

Anavex Life Sciences Corporation (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corporation stock is traded at $8.27, with a volume of 1.72M. It is up +4.55% in the last 24 hours and down -4.28% over the past month. Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Previous Close:

$7.91

Open:

$7.97

24h Volume:

1.72M

Relative Volume:

1.01

Market Cap:

$693.70M

Revenue:

Net Income/Loss:

$-43.16M

P/E Ratio:

-15.04

EPS:

-0.55

Net Cash Flow:

$-29.31M

1W Performance:

+0.12%

1M Performance:

-4.28%

6M Performance:

+51.47%

1Y Performance:

+56.63%

1-Day Range:

$7.95

$8.72

1-Week Range:

$7.71

$8.72

52-Week Range:

$3.25

$14.44

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corporation

Sector

Healthcare (1189)

Industry

Biotechnology (682)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2024-12-31

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corporation	8.27	693.70M	0	-43.16M	-29.31M	-0.55
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corporation Stock (AVXL) Latest News

Feb 28, 2025

AVXL LAWSUIT ALERT: Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Anavex Life Sciences Corp. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 27, 2025

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Feb 27, 2025

Anavex Life Sciences Corp. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In The Near Future - Yahoo Finance

Feb 27, 2025

Levi & Korsinsky Reminds Anavex Life Sciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024AVXL - ACCESS Newswire

Feb 27, 2025

Feb 26, 2025

When Will Anavex Life Sciences Corp. (NASDAQ:AVXL) Breakeven? - Simply Wall St

Feb 26, 2025

Feb 25, 2025

Shareholders that lost money on Anavex Life Sciences Corporation (AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire

Feb 25, 2025

Feb 24, 2025

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times

Feb 24, 2025

Can Anavex's Neurology Pipeline Transform Alzheimer's Treatment? CEO Presents Latest Progress - StockTitan

Feb 24, 2025

Feb 22, 2025

Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC Wainwright - MarketBeat

Feb 22, 2025

Feb 19, 2025

Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your RightsAVXL - ACCESS Newswire

Feb 19, 2025

IMMINENT AVXL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Anavex Life Sciences Corp. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 19, 2025

UPCOMING AVXL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Anavex Life Sciences Corp. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 19, 2025

AVXL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors Can Join the Class Action Lawsuit - ACCESS Newswire

Feb 19, 2025

Feb 18, 2025

Anavex Life Sciences Corporation Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAVXL - ACCESS Newswire

Feb 18, 2025

Wainwright maintains $42 target on Anavex Life Sciences stock By Investing.com - Investing.com Nigeria

Feb 18, 2025

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Anavex Life Sciences Corp. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 18, 2025

Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Feb 18, 2025

Wainwright maintains $42 target on Anavex Life Sciences stock - Investing.com

Feb 18, 2025

AVXL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Anavex Life Sciences Corp. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 18, 2025

Shareholders of Anavex Life Sciences Corporation Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your RightsAVXL - ACCESS Newswire

Feb 18, 2025

Feb 16, 2025

Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Feb 16, 2025

Feb 15, 2025

D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat

Feb 15, 2025

Earnings call transcript: Anavex Life Sciences Q4 2024 sees net loss, stock rises - MSN

Feb 15, 2025

Feb 14, 2025

Anavex: Looking At Different Statistical Approaches Before EMA Opinion (NASDAQ:AVXL) - Seeking Alpha

Feb 14, 2025

Feb 13, 2025

Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2024 - Marketscreener.com

Feb 12, 2025

ANAVEX LIFE SCIENCES CORP. SEC 10-Q Report - TradingView

Feb 12, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update - The Manila Times

Feb 12, 2025

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot -February 12, 2025 at 07:40 am EST - Marketscreener.com

Feb 12, 2025

Breakthrough: Anavex Alzheimer's Treatment Halts Disease Progression by Over One-Third - StockTitan

Feb 12, 2025

Feb 10, 2025

Analytical Lens: Exploring Anavex Life Sciences Corporation (AVXL)’s Financial Story Through Ratios - The Dwinnex

Feb 10, 2025